Psychedelic Drugs-Global Market Status and Trend Report 2016-2026
Report Summary
Psychedelic Drugs-Global Market Status and Trend Report 2016-2026 offers a comprehensive analysis on Psychedelic Drugs industry, standing on the readers’ perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:
Worldwide and Regional Market Size of Psychedelic Drugs 2016-2021, and development forecast 2022-2026
Main manufacturers/suppliers of Psychedelic Drugs worldwide, with company and product introduction, position in the Psychedelic Drugs market
Market status and development trend of Psychedelic Drugs by types and applications
Cost and profit status of Psychedelic Drugs, and marketing status
Market growth drivers and challengesSince the COVID-19 virus outbreak in December 2019, the disease has spread to almost 100 countries around the globe with the World Health Organization declaring it a public health emergency.The global impacts of the coronavirus disease 2019 (COVID-19) are already starting to be felt, and will significantly affect the Ammonium Psychedelic Drugs market in 2020.COVID-19 can affect the global economy in three main ways: by directly affecting production and demand, by creating supply chain and market disruption, and by its financial impact on firms and financial markets.The outbreak of COVID-19 has brought effects on many aspects, like flight cancellations; travel bans and quarantines; restaurants closed; all indoor events restricted; over forty countries state of emergency declared; massive slowing of the supply chain; stock market volatility; falling business confidence, growing panic among the population, and uncertainty about future.This report also analyses the impact of Coronavirus COVID-19 on the Psychedelic Drugs industry.
The report segments the global Psychedelic Drugs market as:
Global Psychedelic Drugs Market: Regional Segment Analysis (Regional Production Volume, Consumption Volume, Revenue and Growth Rate 2016-2026):
North America
Europe
China
Japan
Rest APAC
Latin America
Global Psychedelic Drugs Market: Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2016-2026):
Psilocybin
LSD
MDMA
DMT
Ketamine
Others
Global Psychedelic Drugs Market: Application Segment Analysis (Consumption Volume and Market Share 2016-2026; Downstream Customers and Market Analysis)
Depressive Disorders
Post-Traumatic Stress Disorders
Substance Abuse Disorders
Obsessive Compulsive Disorders
Others
Global Psychedelic Drugs Market: Manufacturers Segment Analysis (Company and Product introduction, Psychedelic Drugs Sales Volume, Revenue, Price and Gross Margin):
COMPASS Pathways PLC
Pfizer
Eli Lilly
GlaxoSmithKline
Cybin Inc
Field Trip Health
ATAI Life Sciences
NUMINUS WELLNESS
MindMed
HAVN Life Sciences
Seelos Therapeutics
Jannsen
Acadia Pharmaceuticals
Intellipharmaceutics
Revive Therapeutics
Mydecine Innovations Group
Red Light Holland
Braxia Scientific
Mind Cure Health
Entheon Biomedical
In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.
Psychedelic Drugs-Global Market Status and Trend Report 2016-2026 offers a comprehensive analysis on Psychedelic Drugs industry, standing on the readers’ perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:
Worldwide and Regional Market Size of Psychedelic Drugs 2016-2021, and development forecast 2022-2026
Main manufacturers/suppliers of Psychedelic Drugs worldwide, with company and product introduction, position in the Psychedelic Drugs market
Market status and development trend of Psychedelic Drugs by types and applications
Cost and profit status of Psychedelic Drugs, and marketing status
Market growth drivers and challengesSince the COVID-19 virus outbreak in December 2019, the disease has spread to almost 100 countries around the globe with the World Health Organization declaring it a public health emergency.The global impacts of the coronavirus disease 2019 (COVID-19) are already starting to be felt, and will significantly affect the Ammonium Psychedelic Drugs market in 2020.COVID-19 can affect the global economy in three main ways: by directly affecting production and demand, by creating supply chain and market disruption, and by its financial impact on firms and financial markets.The outbreak of COVID-19 has brought effects on many aspects, like flight cancellations; travel bans and quarantines; restaurants closed; all indoor events restricted; over forty countries state of emergency declared; massive slowing of the supply chain; stock market volatility; falling business confidence, growing panic among the population, and uncertainty about future.This report also analyses the impact of Coronavirus COVID-19 on the Psychedelic Drugs industry.
The report segments the global Psychedelic Drugs market as:
Global Psychedelic Drugs Market: Regional Segment Analysis (Regional Production Volume, Consumption Volume, Revenue and Growth Rate 2016-2026):
North America
Europe
China
Japan
Rest APAC
Latin America
Global Psychedelic Drugs Market: Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2016-2026):
Psilocybin
LSD
MDMA
DMT
Ketamine
Others
Global Psychedelic Drugs Market: Application Segment Analysis (Consumption Volume and Market Share 2016-2026; Downstream Customers and Market Analysis)
Depressive Disorders
Post-Traumatic Stress Disorders
Substance Abuse Disorders
Obsessive Compulsive Disorders
Others
Global Psychedelic Drugs Market: Manufacturers Segment Analysis (Company and Product introduction, Psychedelic Drugs Sales Volume, Revenue, Price and Gross Margin):
COMPASS Pathways PLC
Pfizer
Eli Lilly
GlaxoSmithKline
Cybin Inc
Field Trip Health
ATAI Life Sciences
NUMINUS WELLNESS
MindMed
HAVN Life Sciences
Seelos Therapeutics
Jannsen
Acadia Pharmaceuticals
Intellipharmaceutics
Revive Therapeutics
Mydecine Innovations Group
Red Light Holland
Braxia Scientific
Mind Cure Health
Entheon Biomedical
In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.
CHAPTER 1 OVERVIEW OF PSYCHEDELIC DRUGS
1.1 Definition of Psychedelic Drugs in This Report
1.2 Commercial Types of Psychedelic Drugs
1.2.1 Psilocybin
1.2.2 LSD
1.2.3 MDMA
1.2.4 DMT
1.2.5 Ketamine
1.2.6 Others
1.3 Downstream Application of Psychedelic Drugs
1.3.1 Depressive Disorders
1.3.2 Post-Traumatic Stress Disorders
1.3.3 Substance Abuse Disorders
1.3.4 Obsessive Compulsive Disorders
1.3.5 Others
1.4 Development History of Psychedelic Drugs
1.5 Market Status and Trend of Psychedelic Drugs 2016-2026
1.5.1 Global Psychedelic Drugs Market Status and Trend 2016-2026
1.5.2 Regional Psychedelic Drugs Market Status and Trend 2016-2026
CHAPTER 2 GLOBAL MARKET STATUS AND FORECAST BY REGIONS
2.1 Market Development of Psychedelic Drugs 2016-2021
2.2 Production Market of Psychedelic Drugs by Regions
2.2.1 Production Volume of Psychedelic Drugs by Regions
2.2.2 Production Value of Psychedelic Drugs by Regions
2.3 Demand Market of Psychedelic Drugs by Regions
2.4 Production and Demand Status of Psychedelic Drugs by Regions
2.4.1 Production and Demand Status of Psychedelic Drugs by Regions 2016-2021
2.4.2 Import and Export Status of Psychedelic Drugs by Regions 2016-2021
CHAPTER 3 GLOBAL MARKET STATUS AND FORECAST BY TYPES
3.1 Production Volume of Psychedelic Drugs by Types
3.2 Production Value of Psychedelic Drugs by Types
3.3 Market Forecast of Psychedelic Drugs by Types
CHAPTER 4 GLOBAL MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY
4.1 Demand Volume of Psychedelic Drugs by Downstream Industry
4.2 Market Forecast of Psychedelic Drugs by Downstream Industry
CHAPTER 5 MARKET DRIVING FACTOR ANALYSIS OF PSYCHEDELIC DRUGS
5.1 Global Economy Situation and Trend Overview
5.2 Psychedelic Drugs Downstream Industry Situation and Trend Overview
CHAPTER 6 PSYCHEDELIC DRUGS MARKET COMPETITION STATUS BY MAJOR MANUFACTURERS
6.1 Production Volume of Psychedelic Drugs by Major Manufacturers
6.2 Production Value of Psychedelic Drugs by Major Manufacturers
6.3 Basic Information of Psychedelic Drugs by Major Manufacturers
6.3.1 Headquarters Location and Established Time of Psychedelic Drugs Major Manufacturer
6.3.2 Employees and Revenue Level of Psychedelic Drugs Major Manufacturer
6.4 Market Competition News and Trend
6.4.1 Merger, Consolidation or Acquisition News
6.4.2 Investment or Disinvestment News
6.4.3 New Product Development and Launch
CHAPTER 7 PSYCHEDELIC DRUGS MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA
7.1 COMPASS Pathways PLC
7.1.1 Company profile
7.1.2 Representative Psychedelic Drugs Product
7.1.3 Psychedelic Drugs Sales, Revenue, Price and Gross Margin of COMPASS Pathways PLC
7.2 Pfizer
7.2.1 Company profile
7.2.2 Representative Psychedelic Drugs Product
7.2.3 Psychedelic Drugs Sales, Revenue, Price and Gross Margin of Pfizer
7.3 Eli Lilly
7.3.1 Company profile
7.3.2 Representative Psychedelic Drugs Product
7.3.3 Psychedelic Drugs Sales, Revenue, Price and Gross Margin of Eli Lilly
7.4 GlaxoSmithKline
7.4.1 Company profile
7.4.2 Representative Psychedelic Drugs Product
7.4.3 Psychedelic Drugs Sales, Revenue, Price and Gross Margin of GlaxoSmithKline
7.5 Cybin Inc
7.5.1 Company profile
7.5.2 Representative Psychedelic Drugs Product
7.5.3 Psychedelic Drugs Sales, Revenue, Price and Gross Margin of Cybin Inc
7.6 Field Trip Health
7.6.1 Company profile
7.6.2 Representative Psychedelic Drugs Product
7.6.3 Psychedelic Drugs Sales, Revenue, Price and Gross Margin of Field Trip Health
7.7 ATAI Life Sciences
7.7.1 Company profile
7.7.2 Representative Psychedelic Drugs Product
7.7.3 Psychedelic Drugs Sales, Revenue, Price and Gross Margin of ATAI Life Sciences
7.8 NUMINUS WELLNESS
7.8.1 Company profile
7.8.2 Representative Psychedelic Drugs Product
7.8.3 Psychedelic Drugs Sales, Revenue, Price and Gross Margin of NUMINUS WELLNESS
7.9 MindMed
7.9.1 Company profile
7.9.2 Representative Psychedelic Drugs Product
7.9.3 Psychedelic Drugs Sales, Revenue, Price and Gross Margin of MindMed
7.10 HAVN Life Sciences
7.10.1 Company profile
7.10.2 Representative Psychedelic Drugs Product
7.10.3 Psychedelic Drugs Sales, Revenue, Price and Gross Margin of HAVN Life Sciences
7.11 Seelos Therapeutics
7.11.1 Company profile
7.11.2 Representative Psychedelic Drugs Product
7.11.3 Psychedelic Drugs Sales, Revenue, Price and Gross Margin of Seelos Therapeutics
7.12 Jannsen
7.12.1 Company profile
7.12.2 Representative Psychedelic Drugs Product
7.12.3 Psychedelic Drugs Sales, Revenue, Price and Gross Margin of Jannsen
7.13 Acadia Pharmaceuticals
7.13.1 Company profile
7.13.2 Representative Psychedelic Drugs Product
7.13.3 Psychedelic Drugs Sales, Revenue, Price and Gross Margin of Acadia Pharmaceuticals
7.14 Intellipharmaceutics
7.14.1 Company profile
7.14.2 Representative Psychedelic Drugs Product
7.14.3 Psychedelic Drugs Sales, Revenue, Price and Gross Margin of Intellipharmaceutics
7.15 Revive Therapeutics
7.15.1 Company profile
7.15.2 Representative Psychedelic Drugs Product
7.15.3 Psychedelic Drugs Sales, Revenue, Price and Gross Margin of Revive Therapeutics
7.16 Mydecine Innovations Group
7.17 Red Light Holland
7.18 Braxia Scientific
7.19 Mind Cure Health
7.20 Entheon Biomedical
CHAPTER 8 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF PSYCHEDELIC DRUGS
8.1 Industry Chain of Psychedelic Drugs
8.2 Upstream Market and Representative Companies Analysis
8.3 Downstream Market and Representative Companies Analysis
CHAPTER 9 COST AND GROSS MARGIN ANALYSIS OF PSYCHEDELIC DRUGS
9.1 Cost Structure Analysis of Psychedelic Drugs
9.2 Raw Materials Cost Analysis of Psychedelic Drugs
9.3 Labor Cost Analysis of Psychedelic Drugs
9.4 Manufacturing Expenses Analysis of Psychedelic Drugs
CHAPTER 10 MARKETING STATUS ANALYSIS OF PSYCHEDELIC DRUGS
10.1 Marketing Channel
10.1.1 Direct Marketing
10.1.2 Indirect Marketing
10.1.3 Marketing Channel Development Trend
10.2 Market Positioning
10.2.1 Pricing Strategy
10.2.2 Brand Strategy
10.2.3 Target Client
10.3 Distributors/Traders List
CHAPTER 11 REPORT CONCLUSION
CHAPTER 12 RESEARCH METHODOLOGY AND REFERENCE
12.1 Methodology/Research Approach
12.1.1 Research Programs/Design
12.1.2 Market Size Estimation
12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Reference
1.1 Definition of Psychedelic Drugs in This Report
1.2 Commercial Types of Psychedelic Drugs
1.2.1 Psilocybin
1.2.2 LSD
1.2.3 MDMA
1.2.4 DMT
1.2.5 Ketamine
1.2.6 Others
1.3 Downstream Application of Psychedelic Drugs
1.3.1 Depressive Disorders
1.3.2 Post-Traumatic Stress Disorders
1.3.3 Substance Abuse Disorders
1.3.4 Obsessive Compulsive Disorders
1.3.5 Others
1.4 Development History of Psychedelic Drugs
1.5 Market Status and Trend of Psychedelic Drugs 2016-2026
1.5.1 Global Psychedelic Drugs Market Status and Trend 2016-2026
1.5.2 Regional Psychedelic Drugs Market Status and Trend 2016-2026
CHAPTER 2 GLOBAL MARKET STATUS AND FORECAST BY REGIONS
2.1 Market Development of Psychedelic Drugs 2016-2021
2.2 Production Market of Psychedelic Drugs by Regions
2.2.1 Production Volume of Psychedelic Drugs by Regions
2.2.2 Production Value of Psychedelic Drugs by Regions
2.3 Demand Market of Psychedelic Drugs by Regions
2.4 Production and Demand Status of Psychedelic Drugs by Regions
2.4.1 Production and Demand Status of Psychedelic Drugs by Regions 2016-2021
2.4.2 Import and Export Status of Psychedelic Drugs by Regions 2016-2021
CHAPTER 3 GLOBAL MARKET STATUS AND FORECAST BY TYPES
3.1 Production Volume of Psychedelic Drugs by Types
3.2 Production Value of Psychedelic Drugs by Types
3.3 Market Forecast of Psychedelic Drugs by Types
CHAPTER 4 GLOBAL MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY
4.1 Demand Volume of Psychedelic Drugs by Downstream Industry
4.2 Market Forecast of Psychedelic Drugs by Downstream Industry
CHAPTER 5 MARKET DRIVING FACTOR ANALYSIS OF PSYCHEDELIC DRUGS
5.1 Global Economy Situation and Trend Overview
5.2 Psychedelic Drugs Downstream Industry Situation and Trend Overview
CHAPTER 6 PSYCHEDELIC DRUGS MARKET COMPETITION STATUS BY MAJOR MANUFACTURERS
6.1 Production Volume of Psychedelic Drugs by Major Manufacturers
6.2 Production Value of Psychedelic Drugs by Major Manufacturers
6.3 Basic Information of Psychedelic Drugs by Major Manufacturers
6.3.1 Headquarters Location and Established Time of Psychedelic Drugs Major Manufacturer
6.3.2 Employees and Revenue Level of Psychedelic Drugs Major Manufacturer
6.4 Market Competition News and Trend
6.4.1 Merger, Consolidation or Acquisition News
6.4.2 Investment or Disinvestment News
6.4.3 New Product Development and Launch
CHAPTER 7 PSYCHEDELIC DRUGS MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA
7.1 COMPASS Pathways PLC
7.1.1 Company profile
7.1.2 Representative Psychedelic Drugs Product
7.1.3 Psychedelic Drugs Sales, Revenue, Price and Gross Margin of COMPASS Pathways PLC
7.2 Pfizer
7.2.1 Company profile
7.2.2 Representative Psychedelic Drugs Product
7.2.3 Psychedelic Drugs Sales, Revenue, Price and Gross Margin of Pfizer
7.3 Eli Lilly
7.3.1 Company profile
7.3.2 Representative Psychedelic Drugs Product
7.3.3 Psychedelic Drugs Sales, Revenue, Price and Gross Margin of Eli Lilly
7.4 GlaxoSmithKline
7.4.1 Company profile
7.4.2 Representative Psychedelic Drugs Product
7.4.3 Psychedelic Drugs Sales, Revenue, Price and Gross Margin of GlaxoSmithKline
7.5 Cybin Inc
7.5.1 Company profile
7.5.2 Representative Psychedelic Drugs Product
7.5.3 Psychedelic Drugs Sales, Revenue, Price and Gross Margin of Cybin Inc
7.6 Field Trip Health
7.6.1 Company profile
7.6.2 Representative Psychedelic Drugs Product
7.6.3 Psychedelic Drugs Sales, Revenue, Price and Gross Margin of Field Trip Health
7.7 ATAI Life Sciences
7.7.1 Company profile
7.7.2 Representative Psychedelic Drugs Product
7.7.3 Psychedelic Drugs Sales, Revenue, Price and Gross Margin of ATAI Life Sciences
7.8 NUMINUS WELLNESS
7.8.1 Company profile
7.8.2 Representative Psychedelic Drugs Product
7.8.3 Psychedelic Drugs Sales, Revenue, Price and Gross Margin of NUMINUS WELLNESS
7.9 MindMed
7.9.1 Company profile
7.9.2 Representative Psychedelic Drugs Product
7.9.3 Psychedelic Drugs Sales, Revenue, Price and Gross Margin of MindMed
7.10 HAVN Life Sciences
7.10.1 Company profile
7.10.2 Representative Psychedelic Drugs Product
7.10.3 Psychedelic Drugs Sales, Revenue, Price and Gross Margin of HAVN Life Sciences
7.11 Seelos Therapeutics
7.11.1 Company profile
7.11.2 Representative Psychedelic Drugs Product
7.11.3 Psychedelic Drugs Sales, Revenue, Price and Gross Margin of Seelos Therapeutics
7.12 Jannsen
7.12.1 Company profile
7.12.2 Representative Psychedelic Drugs Product
7.12.3 Psychedelic Drugs Sales, Revenue, Price and Gross Margin of Jannsen
7.13 Acadia Pharmaceuticals
7.13.1 Company profile
7.13.2 Representative Psychedelic Drugs Product
7.13.3 Psychedelic Drugs Sales, Revenue, Price and Gross Margin of Acadia Pharmaceuticals
7.14 Intellipharmaceutics
7.14.1 Company profile
7.14.2 Representative Psychedelic Drugs Product
7.14.3 Psychedelic Drugs Sales, Revenue, Price and Gross Margin of Intellipharmaceutics
7.15 Revive Therapeutics
7.15.1 Company profile
7.15.2 Representative Psychedelic Drugs Product
7.15.3 Psychedelic Drugs Sales, Revenue, Price and Gross Margin of Revive Therapeutics
7.16 Mydecine Innovations Group
7.17 Red Light Holland
7.18 Braxia Scientific
7.19 Mind Cure Health
7.20 Entheon Biomedical
CHAPTER 8 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF PSYCHEDELIC DRUGS
8.1 Industry Chain of Psychedelic Drugs
8.2 Upstream Market and Representative Companies Analysis
8.3 Downstream Market and Representative Companies Analysis
CHAPTER 9 COST AND GROSS MARGIN ANALYSIS OF PSYCHEDELIC DRUGS
9.1 Cost Structure Analysis of Psychedelic Drugs
9.2 Raw Materials Cost Analysis of Psychedelic Drugs
9.3 Labor Cost Analysis of Psychedelic Drugs
9.4 Manufacturing Expenses Analysis of Psychedelic Drugs
CHAPTER 10 MARKETING STATUS ANALYSIS OF PSYCHEDELIC DRUGS
10.1 Marketing Channel
10.1.1 Direct Marketing
10.1.2 Indirect Marketing
10.1.3 Marketing Channel Development Trend
10.2 Market Positioning
10.2.1 Pricing Strategy
10.2.2 Brand Strategy
10.2.3 Target Client
10.3 Distributors/Traders List
CHAPTER 11 REPORT CONCLUSION
CHAPTER 12 RESEARCH METHODOLOGY AND REFERENCE
12.1 Methodology/Research Approach
12.1.1 Research Programs/Design
12.1.2 Market Size Estimation
12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Reference
